|
1
|
Mulliken JB, Fishman SJ and Burrows PE:
Vascular anomalies. Curr Probl Surg. 37:517–584. 2000. View Article : Google Scholar
|
|
2
|
Xu L, Hausmann M, Dietmaier W, et al:
Expression of growth factor receptors and targeting of EGFR in
cholangiocarcinoma cell lines. BMC Cancer. 10:3022010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tovar V, Alsinet C, Villanueva A, et al:
IGF activation in a molecular subclass of hepatocellular carcinoma
and pre-clinical efficacy of IGF-1R blockage. J Hepatol.
52:550–559. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dong X, Javle M, Hess KR, et al:
Insulin-like growth factor axis gene polymorphisms and clinical
outcomes in pancreatic cancer. Gastroenterology. 139:464–473. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong X, Li Y, Tang H, et al: Insulin-like
growth factor axis gene polymorphisms modify risk of pancreatic
cancer. Cancer Epidemiol. 36:206–211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harris LK and Westwood M: Biology and
significance of signalling pathways activated by IGF-II. Growth
Factors. 30:1–12. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hernandez L, Kozlov S, Piras G, et al:
Paternal and maternal genomes confer opposite effects on
proliferation, cell-cycle length, senescence, and tumor formation.
Proc Natl Acad Sci USA. 100:13344–13349. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kotsinas A, Evangelou K, Sideridou M, et
al: The 3′ UTR IGF2R-A2/B2 variant is associated with increased
tumor growth and advanced stages in non-small cell lung cancer.
Cancer Lett. 259:177–185. 2008.
|
|
9
|
Zavras AI, Pitiphat W, Wu T, et al:
Insulin-like growth factor II receptor gene-167 genotype increases
the risk of oral squamous cell carcinoma in humans. Cancer Res.
63:296–297. 2003.PubMed/NCBI
|
|
10
|
Yoon AJ, Zavras AI, Chen MK, et al:
Association between Gly1619ARG polymorphism of IGF2R domain 11
(rs629849) and advanced stage of oral cancer. Med Oncol.
29:682–685. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoyo C, Schildkraut JM, Murphy SK, et al:
IGF2R polymorphisms and risk of esophageal and gastric
adenocarcinomas. Int J Cancer. 125:2673–2678. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lönn S, Rothman N, Shapiro WR, et al:
Genetic variation in insulin-like growth factors and brain tumor
risk. Neuro Oncol. 10:553–559. 2008.PubMed/NCBI
|
|
13
|
Kalla Singh S, Tan QW, Brito C, et al:
Insulin-like growth factors I and II receptors in the breast cancer
survival disparity among African-American women. Growth Horm IGF
Res. 20:245–254. 2010.PubMed/NCBI
|
|
14
|
Hu CK, McCall S, Madden J, et al: Loss of
heterozygosity of M6P/IGF2R gene is an early event in the
development of prostate cancer. Prostate Cancer Prostatic Dis.
9:62–67. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen Z, Ge Y, Landman N, et al: Decreased
expression of the mannose 6-phosphate/insulin-like growth factor-II
receptor promotes growth of human breast cancer cells. BMC Cancer.
2:182002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oka Y, Waterland RA, Killian JK, et al:
M6P/IGF2R tumor suppressor gene mutated in hepatocellular
carcinomas in Japan. Hepatology. 35:1153–1163. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang EB, Qin LL, Zhao YN, et al: Genetic
changes and expression of the mannose 6-phosphate/insulin-like
growth factor II receptor gene in human hepatitis B
virus-associated hepatocellular carcinoma. Int J Mol Med.
11:773–778. 2003.
|
|
18
|
Schiller HB, Szekeres A, Binder BR, et al:
Mannose 6-phosphate/insulin-like growth factor 2 receptor limits
cell invasion by controlling alphaVbeta3 integrin expression and
proteolytic processing of urokinase-type plasminogen activator
receptor. Mol Biol Cell. 20:745–756. 2009. View Article : Google Scholar
|
|
19
|
Probst OC, Puxbaum V, Svoboda B, et al:
The mannose 6-phosphate/insulin-like growth factor II receptor
restricts the tumourigenicity and invasiveness of squamous cell
carcinoma cells. Int J Cancer. 124:2559–2567. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ji Y, Chen S, Li K, et al: Signaling
pathways in the development of infantile hemangioma. J Hematol
Oncol. 7:132014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amin RM, Hiroshima K, Miyagi Y, et al:
Role of the PI3K/Akt, mTOR, and STK11/LKB1 pathways in the
tumorigenesis of sclerosing hemangioma of the lung. Pathol Int.
58:38–44. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brown J, Jones EY and Forbes BE:
Interactions of IGF-II with the IGF2R/cation-independent
mannose-6-phosphate receptor mechanism and biological outcomes.
Vitam Horm. 80:699–719. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Klopfleisch R, Hvid H, Klose P, et al:
Insulin receptor is expressed in normal canine mammary gland and
benign adenomas but decreased in metastatic canine mammary
carcinomas similar to human breast cancer. Vet Comp Oncol.
8:293–301. 2010. View Article : Google Scholar
|
|
24
|
Puxbaum V, Nimmerfall E, Bäuerl C, et al:
M6P/IGF2R modulates the invasiveness of liver cells via its
capacity to bind mannose 6-phosphate residues. J Hepatol.
57:337–343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gelman MS, Ye XK, Stull R, et al:
Identification of cell surface and secreted proteins essential for
tumor cell survival using a genetic suppressor element screen.
Oncogene. 23:8158–8170. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shin DM, Hittelman WN and Hong WK:
Biomarkers in upper aerodigestive tract tumorigenesis: a review.
Cancer Epidemiol Biomarkers Prev. 3:697–709. 1994.PubMed/NCBI
|
|
27
|
Kelly PN and Strasser A: The role of Bcl-2
and its pro-survival relatives in tumourigenesis and cancer
therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim JK and Diehl JA: Nuclear cyclin D1: an
oncogenic driver in human cancer. J Cell Physiol. 220:292–296.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan ST, Velickovic M, Ruger BM, et al:
Cellular and extracellular markers of hemangioma. Plast Reconstr
Surg. 106:529–538. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Murakami M, Sakai H, Kodama A, et al:
Expression of the anti-apoptotic factors Bcl-2 and survivin in
canine vascular tumours. J Comp Pathol. 139:1–7. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mohamed AM, Elwakil TF, Taher IM, et al:
Cyclin D1 gene amplification in proliferating haemangioma. Cell
Tissue Res. 338:107–115. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakamura T: Apoptosis and expression of
Bax/Bcl-2 proteins in pyogenic granuloma: a comparative study with
granulation tissue and capillary hemangioma. J Cutan Pathol.
27:400–405. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fu Y, Zhang Q, Kang C, et al: Inhibitory
effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth
of malignant tumor cells in vitro and in vivo. Cancer Biol Ther.
8:1002–1009. 2009. View Article : Google Scholar
|
|
34
|
Raja Singh P, Arunkumar R, Sivakamasundari
V, et al: Anti-proliferative and apoptosis inducing effect of
nimbolide by altering molecules involved in apoptosis and IGF
signalling via PI3K/AKT in prostate cancer (PC-3) cell line. Cell
Biochem Funct. 32:217–228. 2014.PubMed/NCBI
|
|
35
|
Chen C, Chang YC, Lan MS, et al: Leptin
stimulates ovarian cancer cell growth and inhibits apoptosis by
increasing cyclin D1 and Mcl-1 expression via the activation of the
MEK/ERK1/2 and PI3K/Akt signaling pathways. Int J Oncol.
42:1113–1119. 2013.PubMed/NCBI
|
